Tom Daniel, MD
Tom Daniel, MD, a nephrologist and former academic investigator, is a Venture Partner at ARCH Venture Partners. He also serves as Chairman of Locana Bio and as a Director at Vividion Therapeutics, Magenta Therapeutics, ImmunsanT, Zafgen, and the Alliance for Lupus Research. He is a trustee of Reed College, serves on the Biomedical Science Advisory Board of Vanderbilt University Medical Center, and is a Senior Advisor to BlackThorn Therapeutics.
Most recently, Tom was President of Global Research and Early Development at Celgene Corporation for more than 10 years as the company emerged as a leader in defining new mechanisms for drug action, established industry leading collaborative networks, and advanced / commercialized innovative medicines in oncology and inflammatory diseases. Prior to that, Tom served as Chief Scientific Officer and Director of AmbRx, as Vice President of Research at Amgen, and as Senior Vice President of Discovery Research at Immunex Corporation. Previously, he was C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University.
Tom earned his MD from the University of Texas, Southwestern (UTSW), trained in molecular genetics at UTSW and completed a medical residency at Massachusetts General Hospital.